JPH04505623A - イムノアッセイにおいて利用するためのシステインチオール保護ペプチド - Google Patents
イムノアッセイにおいて利用するためのシステインチオール保護ペプチドInfo
- Publication number
- JPH04505623A JPH04505623A JP2510450A JP51045090A JPH04505623A JP H04505623 A JPH04505623 A JP H04505623A JP 2510450 A JP2510450 A JP 2510450A JP 51045090 A JP51045090 A JP 51045090A JP H04505623 A JPH04505623 A JP H04505623A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cys
- protected
- peptides
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 320
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 66
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 title claims abstract 4
- 238000003018 immunoassay Methods 0.000 title description 22
- 235000018102 proteins Nutrition 0.000 claims abstract description 23
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 23
- 239000000427 antigen Substances 0.000 claims abstract description 20
- 102000036639 antigens Human genes 0.000 claims abstract description 20
- 108091007433 antigens Proteins 0.000 claims abstract description 20
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims abstract description 16
- 241001430294 unidentified retrovirus Species 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 52
- 235000001014 amino acid Nutrition 0.000 claims description 38
- 150000001413 amino acids Chemical class 0.000 claims description 38
- 239000007790 solid phase Substances 0.000 claims description 37
- 239000004816 latex Substances 0.000 claims description 26
- 229920000126 latex Polymers 0.000 claims description 26
- 230000002441 reversible effect Effects 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 22
- 230000003647 oxidation Effects 0.000 claims description 21
- 238000007254 oxidation reaction Methods 0.000 claims description 21
- -1 ethylcarbamoyl Chemical group 0.000 claims description 20
- 230000009257 reactivity Effects 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 11
- 230000027455 binding Effects 0.000 claims description 10
- 210000001124 body fluid Anatomy 0.000 claims description 10
- 239000010839 body fluid Substances 0.000 claims description 10
- 230000001900 immune effect Effects 0.000 claims description 10
- 238000001179 sorption measurement Methods 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 7
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 6
- 238000011002 quantification Methods 0.000 claims description 6
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 5
- 239000004793 Polystyrene Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000003100 immobilizing effect Effects 0.000 claims description 5
- 230000036046 immunoreaction Effects 0.000 claims description 5
- 238000002372 labelling Methods 0.000 claims description 5
- 229920002401 polyacrylamide Polymers 0.000 claims description 5
- 229920002223 polystyrene Polymers 0.000 claims description 5
- 239000011541 reaction mixture Substances 0.000 claims description 5
- 230000001177 retroviral effect Effects 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 239000004677 Nylon Substances 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000007795 chemical reaction product Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 229920002313 fluoropolymer Polymers 0.000 claims description 4
- 229920001778 nylon Polymers 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 abstract description 23
- 241000713340 Human immunodeficiency virus 2 Species 0.000 abstract description 23
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 abstract description 9
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 abstract description 7
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 abstract description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 239000011324 bead Substances 0.000 description 56
- 229940024606 amino acid Drugs 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 21
- 239000012528 membrane Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 16
- 241000700605 Viruses Species 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 11
- 239000006166 lysate Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 229960003067 cystine Drugs 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 101800000385 Transmembrane protein Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000003278 mimic effect Effects 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- DZLQXIFVQFTFJY-BYPYZUCNSA-N Cys-Gly-Gly Chemical compound SC[C@H](N)C(=O)NCC(=O)NCC(O)=O DZLQXIFVQFTFJY-BYPYZUCNSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000002820 assay format Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000012898 sample dilution Substances 0.000 description 3
- 239000002344 surface layer Substances 0.000 description 3
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FDEOPFSXGJBPRR-BYPYZUCNSA-N (2r)-2-azaniumyl-3-(ethylcarbamoylsulfanyl)propanoate Chemical compound CCNC(=O)SC[C@H]([NH3+])C([O-])=O FDEOPFSXGJBPRR-BYPYZUCNSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003156 radioimmunoprecipitation Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 1
- JTNGEYANGCBZLK-UHFFFAOYSA-N 1h-indol-3-yl dihydrogen phosphate Chemical compound C1=CC=C2C(OP(O)(=O)O)=CNC2=C1 JTNGEYANGCBZLK-UHFFFAOYSA-N 0.000 description 1
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
- WCVOGSZTONGSQY-UHFFFAOYSA-N 2,4,6-trichloroanisole Chemical compound COC1=C(Cl)C=C(Cl)C=C1Cl WCVOGSZTONGSQY-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical class OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100033620 Calponin-1 Human genes 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 241001212789 Dynamis Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001669573 Galeorhinus galeus Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101800005164 Peptide V Proteins 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 241000231739 Rutilus rutilus Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000015115 caffè latte Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- CYFJIBWZIQDUSZ-UHFFFAOYSA-N thioglycine Chemical group NCC(S)=O CYFJIBWZIQDUSZ-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (47)
- 1.天然のタンパク質に対する抗体と免疫的に反応するペプチド組成物であって 、該ペプチドが6個から50個のアミノ酸のアミノ酸配列を含んで成り、そして 該配列が2個のCys残基であってそれらが互いに少なくとも約2個、しかしな がら20個より少ない非Cysアミノ酸残基により離されているものを含んで成 り、そして該Cys残基のチオール基が化学的可逆性手段により可逆的に保護さ れている、ペプチド組成物。
- 2.請求項1に記載のペプチドであって、前記Cys残基がエチルカルバモイル 、アセタミドメチル、3−ニトロ−2−ピリジンスルフィニル又はジフェニル− 4−ピリジルメチルにより、酸化から保護されているペプチド。
- 3.請求項2に記載のペプチドであって、前記Cys残基がエチルカルバモイル により、酸化から保護されているペプチド。
- 4.請求項1に記載のペプチドであって、酸化から保護されていないCys残基 をN−末端に更に含んで成るペプチド。
- 5.請求項4に記載のペプチドであって、前記のN−末端のアミノ酸がCys− Gly−Glyを含んで成るペプチド。
- 6.請求項4に記載のペプチドであって、そのC−末端アミノ酸がアミド化され ているペプチド。
- 7.請求項1に記載のペプチドであって、前記のCys残基が互いから約4個か ら6個の非Cys残基により離れているペプチド。
- 8.請求項1に記載のペプチドであって、レトロウィルスのトランスメンプラン タンパク質に対する抗体と免疫的に反応するペプチド。
- 9.請求項8に記載のペプチドであって、前記のレトロウィルスタンパク質がH IV−1gp41であり、該ペプチドが以下の配列: 【配列があります】 における少なくとも7個の隣接するアミノ酸を含んで成るペプチド。
- 10.請求項9に記載のペプチドであって、そのN−末端が免疫特異的反応性を 高めるために付加されているアミノ酸を含んで成り、ここで該付加されているア ミノ酸の少なくとも1つは酸化から保護されていないCys残基である、ペプチ ド。
- 11.請求項10に記載のペプチドであって、前記の酸化から保護されていない CysがN−末端残基であるペプチド。
- 12.請求項11に記載のペプチドであって、前記のN−末端配列がCys−G ly−Glyであるペプチド。
- 13.請求項11に記載のペプチドであって、そのC−末端のアミノ酸がアミド 化されているペプチド。
- 14.請求項8に記載のペプチドであって、前記のレトロウィルスのタンパク質 がHIV−2gp36であり、そして該ペプチドが以下の配列: 【配列があります】 における少なくとも7個の隣接するアミノ酸を含んで成るペプチド。
- 15.請求項14に記載のペプチドであって、そのN−末端が免疫特異的反応性 を高めるために付加されているアミノ酸を含んで成り、ここで該付加されている アミノ酸の少なくとも1つが酸化から保護されていないCys残基である、ペプ チド。
- 16.請求項15に記載のペプチドであって、前記の酸化から保護されていない Cys残基がN末端の残基であるペプチド。
- 17.請求項16に記載のペプチドであって、前記のN−末端配列がCys−G ly−Glyであるペプチド。
- 18.請求項16に記載のペプチドであって、そのC末端のアミノ酸がアミド化 されているペプチド。
- 19.請求項8に記載のペプチドであって、前記のレトロウィルスのトランスメ ンプランタンパク質がHTLV−1gp21であり、そして該ペプチドが以下の 配列:【配列があります】 における少なくとも7個の隣接するアミノ酸を含んで成るペプチド。
- 20.請求項19に記載のペプチドであって、そのN−末端が免疫特異的反応性 を高めるために付加されているアミノ酸を含んで成り、ここで該付加されている アミノ酸の少なくとも1つが酸化から保護されていないCys残基である、ペプ チド。
- 21.請求項20に記載のペプチドであって、前記の酸化から保護されていない CysがN−末端残基であるペプチド。
- 22.請求項21に記載のペプチドであって、前記のN−末端配列がCys−G ly−Glyであるペプチド。
- 23.請求項21に記載のペプチドであって、そのC末端アミノ酸がアミド化さ れているペプチド。
- 24.請求項8に記載のペプチドであって、前記のレトロウィルスのタンパク質 がHTLV−IIgp21であり、そして該ペプチドが以下の配列: 【配列があります】 における少なくとも7個の隣接するアミノ酸を含んで成るペプチド。
- 25.請求項21に記載のペプチドであって、そのN−末端が免疫特異的反応性 を高めるために付加されているアミノ酸を含んで成り、ここで該付加されている アミノ酸の少なくとも1つが酸化から保護されていないCys残基である、ペプ チド。
- 26.請求項25に記載のペプチドであって、前記の酸化から保護されていない Cys残基がN−末端の残基であるペプチド。
- 27.請求項26に記載のペプチドであって、前記のN−末端配列がCys−G ly−Glyであるペプチド。
- 28.請求項26に記載のペプチドであって、そのC−末端アミノ酸がアミド化 されているペプチド。
- 29.タンパク質に対する抗体の免疫学的な検出及び/又は定量のための、ペプ チド被覆されている固相を調製するための方法であって、以下のこと: (a)ペプチドであって6〜50個のアミノ酸のアミノ酸配列を含んで成り、そ して2個のCys残基であってそれぞれが互いから少なくとも約2個しかしなが ら20個より少ない非Cysアミノ酸残基により離されているものを有するペプ チドを合成し; (b)該ペプチド配列内にコード化されているシステイン残基のチオール基を、 保護されているペプチド組成物の形成のために化学的可逆性手段により保護し; (c)該保護されているペプチド組成物を固相に固定化し;(d)該固定化され ているペプチド組成物から該化学的可逆性手段を除去し; (e)該固定化されているペプチド組成物を、ジスルフィド結合の形成が行なえ る条件のもとでインキュベートすること; を含んで成る方法。
- 30.請求項29に記載の方法であって、前記のシステインチオール基を、前記 のペプチドの配列の合成前に保護する方法。
- 31.請求項29に記載の方法であって、前記の化学的可逆性保護手段がエチル カルバモイル、アセタミドメチル、3−ニトロ−2−ピリジンスルフイニル又は ジフェニル−4−ピリジルメチルである方法。
- 32.請求項31に記載の方法であって、前記の化学的可逆性保護手段がエチル カルバモイルである方法。
- 33.請求項29に記載の方法であって、前記のペプチドを吸着により固定化す る方法。
- 34.請求項29に記載の方法であって、前記のペプチドを共有結合により前記 の固相に固定化する方法。
- 35.請求項29に記載の方法であって、前記の固相がラテックス、シリカ、セ ルロース、フルオロカーボンポリマー、ナイロン、ポリアクリルアミド又はポリ スチレンである方法。
- 36.請求項29に記載の方法であって、前記の方法がシリカ、セルロース、ポ リアクリルアミド又はポリスチレンのラテックスである方法。
- 37.請求項35に記載の方法であって、前記の固相がポリスチレンのラテック スである方法。
- 38.請求項29に記載の方法であって、前記のペプチド配列が: 【配列があります】, 【配列があります】,【配列があります】,又は【配列があります】, であり、ここでXがOH又はNH2、Yが反応性を高めるために加えられている アミノ酸を含んで成り、そしてCys*が化学的可逆性手段により保護されたチ オール基を含んで成る、方法。
- 39.体液内のHIVウィルスに対する抗体又はHIVウィルスの抗原の存在を 検出するための方法であって、以下の段階: (a)固相と以下のアミノ酸配列を含んで成る少なくとも1つのペプチドとを、 固定化が可能な条件のもとで接触させ(ここで該アミノ酸配列は: 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】,又は 【配列があります】, であり、XがOH又はNH2であり、Yは該ペプチドの反応性を高めるために付 加されているアミノ酸を含んで成り、そしてCys*は化学的可逆性手段により 保護されているチオール基を含んで成る); (b)該固定化されているペプチドの該システインチオール基から該化学的可逆 性保護手段を除去し;(c)該固定化されているペプチドをジスルフィド結合の 形成の行なわれる条件のもとでインキュベートし;(d)該体液と該固定化され ているペプチドとを、反応混合物を作るために免疫特異的結合が可能な条件のも とで接触させ; (e)免疫特異的結合が該固定化されているペプチドと該体液の抗体成分との間 に生じたかどうかを検出することであって、この免疫特異的結合の検出が該体液 内のHIVウィルスの抗体又は抗原の存在を示唆すること;を含んで成る方法。
- 40.請求項39に記載の方法であって、免疫特異的結合が以下の段階: (a)前記の免疫反応混合物において形成される反応生成物から未結合成分を除 去し; (b)該免疫反応混合物に標識した抗体を加え、(ここで該標識された抗体は該 反応生成物の成分と免疫特異的結合が可能であり、そしてこの標識剤は検出可能 なシグナルを提供する);そして (c)該標識した抗体が該反応生成物と結合したかどうかを検出すること; により検出される方法。
- 41.請求項40に記載の方法であって、前記の未結合成分の除去の段階が濾過 による方法。
- 42.請求項40に記載の方法であって、前記の標識剤が、蛍光物質、酵素、ル ミネッセント化合物、ラジオアイソトープ及び粒子より成るループから選ばれる 方法。
- 43.請求項42に記載の方法であって、前記の標識剤が酵素基質の添加により 検出可能な酵素である方法。
- 44.請求項39に記載の方法であって、前記の固相がラテックス、シリカ、セ ルロース、フルオロカーボンポリマー、ナイロン、ポリアクリルアミド及びポリ スチレンより成るグループから選ばれる方法。
- 45.請求項44に記載の方法であって、前記の固相がポリアクリルアミド、ポ リスチレン、シリカ及びセルロースのラテックスより成るグループから選ばれる 方法。
- 46.請求項44に記載の方法であって、前記の固相がポリスチレンのラテック スである方法。
- 47.HIVウィルスに対する抗体の免疫学的な検出及び/又は定量のための抗 原被覆固相の調製方法であって、以下の段階: (a)ペプチド組成物を合成すること、(ここでその中に一体化されているシス テインチオール基は保護されたペプチド組成物を作るために化学的可逆性手段に より保護されている); (b)該化学的可逆性保護手段を該保護されたペプチド組成物から、分子内ジス ルフィド結合の形成が行える条件のもとで除去し; (c)該ペプチド組成物を固相に固定化して抗原被覆固相を形成せしめること; を含んで成る方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36051389A | 1989-06-02 | 1989-06-02 | |
US360,513 | 1989-06-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04505623A true JPH04505623A (ja) | 1992-10-01 |
JP3404035B2 JP3404035B2 (ja) | 2003-05-06 |
Family
ID=23418295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51045090A Expired - Lifetime JP3404035B2 (ja) | 1989-06-02 | 1990-06-04 | イムノアッセイにおいて利用するためのシステインチオール保護ペプチド |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0474789B1 (ja) |
JP (1) | JP3404035B2 (ja) |
KR (1) | KR960013600B1 (ja) |
AT (1) | ATE162799T1 (ja) |
AU (1) | AU652919B2 (ja) |
CA (1) | CA2056381C (ja) |
DE (1) | DE69032009T2 (ja) |
DK (1) | DK0474789T3 (ja) |
ES (1) | ES2113860T3 (ja) |
FI (1) | FI102834B1 (ja) |
NO (1) | NO304151B1 (ja) |
WO (1) | WO1990015071A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010151528A (ja) * | 2008-12-24 | 2010-07-08 | Chisso Corp | チオール基を有する刺激応答性磁性微粒子及びその利用 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6083504A (en) * | 1989-08-24 | 2000-07-04 | Bioclonetics Incorporated | Human monoclonal antibodies directed against the transmembrane glycoprotein (GP41) of human immunodeficiency virus-1 (HIV-1) |
US6008044A (en) * | 1989-08-24 | 1999-12-28 | Bioclonetics | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) and detection of antibodies against epitope (GCSGKLIC) |
US5459060A (en) * | 1989-08-24 | 1995-10-17 | Bioclonetics Incorporated | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) |
DE69129207T2 (de) * | 1990-01-16 | 1998-10-08 | Orgenics Ltd | Peptide, von Virus-HIV-Hüllen-Glycoproteinen abstammend, deren Verwendung zum Nachweis einer Infektion dieser Viren und für die Impfung gegen AIDS |
CA2387666A1 (en) * | 1999-10-27 | 2001-05-03 | Innogenetics N.V. | Redox reversible hcv proteins with native-like conformation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4111924A (en) * | 1976-01-05 | 1978-09-05 | Takeda Chemical Industries, Ltd. | Method for removal of thiol-protecting groups |
FR2525592B1 (ja) * | 1982-04-26 | 1984-09-14 | Pasteur Institut | |
US4689398A (en) * | 1984-06-20 | 1987-08-25 | Ortho Diagnostic Systems Inc. | HTLV test using synthetic peptides |
ATE98376T1 (de) * | 1986-03-24 | 1993-12-15 | Ortho Pharma Corp | Synthetische htlv-iii-peptid-zusammensetzungen und ihre verwendung. |
EP0247557B1 (en) * | 1986-05-27 | 1994-04-20 | F. Hoffmann-La Roche Ag | HTLV-III(LAV) Envelope peptides |
GB8828097D0 (en) * | 1988-12-01 | 1989-01-05 | Wellcome Found | Peptides |
-
1990
- 1990-06-04 WO PCT/US1990/003148 patent/WO1990015071A1/en active IP Right Grant
- 1990-06-04 KR KR1019910701744A patent/KR960013600B1/ko not_active IP Right Cessation
- 1990-06-04 DK DK90911054T patent/DK0474789T3/da active
- 1990-06-04 AU AU60532/90A patent/AU652919B2/en not_active Expired
- 1990-06-04 CA CA002056381A patent/CA2056381C/en not_active Expired - Lifetime
- 1990-06-04 ES ES90911054T patent/ES2113860T3/es not_active Expired - Lifetime
- 1990-06-04 AT AT90911054T patent/ATE162799T1/de not_active IP Right Cessation
- 1990-06-04 DE DE69032009T patent/DE69032009T2/de not_active Expired - Fee Related
- 1990-06-04 JP JP51045090A patent/JP3404035B2/ja not_active Expired - Lifetime
- 1990-06-04 EP EP90911054A patent/EP0474789B1/en not_active Expired - Lifetime
-
1991
- 1991-11-29 FI FI915649A patent/FI102834B1/fi active
- 1991-11-29 NO NO914725A patent/NO304151B1/no not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010151528A (ja) * | 2008-12-24 | 2010-07-08 | Chisso Corp | チオール基を有する刺激応答性磁性微粒子及びその利用 |
Also Published As
Publication number | Publication date |
---|---|
KR960013600B1 (ko) | 1996-10-09 |
WO1990015071A1 (en) | 1990-12-13 |
FI915649A0 (fi) | 1991-11-29 |
DE69032009T2 (de) | 1998-07-23 |
CA2056381C (en) | 2000-08-22 |
DE69032009D1 (de) | 1998-03-05 |
AU6053290A (en) | 1991-01-07 |
FI102834B (fi) | 1999-02-26 |
EP0474789A1 (en) | 1992-03-18 |
NO914725D0 (no) | 1991-11-29 |
ATE162799T1 (de) | 1998-02-15 |
DK0474789T3 (da) | 1998-09-28 |
AU652919B2 (en) | 1994-09-15 |
CA2056381A1 (en) | 1990-12-03 |
NO914725L (no) | 1992-01-29 |
EP0474789B1 (en) | 1998-01-28 |
KR920701236A (ko) | 1992-08-11 |
NO304151B1 (no) | 1998-11-02 |
EP0474789A4 (en) | 1992-06-03 |
JP3404035B2 (ja) | 2003-05-06 |
ES2113860T3 (es) | 1998-05-16 |
FI102834B1 (fi) | 1999-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7629295B2 (en) | Determination of a specific immunoglobulin using multiple antigens | |
JP2675009B2 (ja) | 改良ペプチド組成物およびhivに対する抗体の検出方法 | |
EP0891982B1 (en) | HIV peptides | |
KR910002374B1 (ko) | Aids 관련질병의 검출을 위한 합성항원 | |
JP2733059B2 (ja) | Htlv−▲iii▼抗体の診断用ペプチド並びにそれらの製造法及び用途 | |
US5439792A (en) | Cysteine thiol-protected peptides for use in immunoassays | |
JPH01500053A (ja) | Htlv−3に対する抗体の検出法 | |
JP3534417B2 (ja) | Hiv抗原及びhiv抗体の同時決定方法 | |
KR100240514B1 (ko) | 멀티머 항원을 사용하는 특이적 면역글로불린의 측정방법 | |
US5241047A (en) | Synthetic peptides and mixtures thereof for detecting HIV antibodies | |
JP3851761B2 (ja) | Hiv抗体を検出するための合成ペプチド及びその混合物 | |
JPH04505623A (ja) | イムノアッセイにおいて利用するためのシステインチオール保護ペプチド | |
AU753780B2 (en) | Synthetic antigen for the detection of antibodies immunoreactive with HIV virus | |
AU623949B2 (en) | Synthetic peptide derivatives of gp41 glycoprotein of HIV | |
US6149910A (en) | Peptides for the detection of HIV-1 group O | |
JPH10259197A (ja) | ペプチド混合物の製造方法 | |
CA2223090C (en) | Improved hapten-peptide conjugates to detect anti-hiv-1 or anti-hiv-2 antibodies | |
JP2002511853A (ja) | Hiv抗体の検出方法及びそれに使用する抗原 | |
JPH02500597A (ja) | Hiv‐1関連ポリペプチド類、診断システム類及びアッセイ方法 | |
CA2004288A1 (en) | Peptides | |
JPH02500590A (ja) | ペプチド | |
JPH01153700A (ja) | エイズ診断用ペプチド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080229 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090228 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090228 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100228 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100228 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110228 Year of fee payment: 8 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110228 Year of fee payment: 8 |